Market Research Future has a half cooked research report on the global [URL=https://www.marketresearchfuture.com/reports/myomectomy-market-5149/]Myomectomy market[/URL] . The global Myomectomy market is growing continuously and is expected to grow at a CAGR of 6.9 % from 2017 to 2023.Market Highlights
Myomectomy is surgical procedure for the removal of uterine fibroids. Uterine fibroid, also known as leiomyoma or myomas, is a non-cancerous growth that develops inside or on the wall of a woman’s uterus. Heavy bleeding between or during the menstrual cycle, pain in pelvis or lower back, increased menstrual cramps are major symptoms for uterine fibroids.
Get Free Sample Copy @ [URL]https://www.marketresearchfuture.com/sample_request/5149/[/URL]
Prevalence of uterine disorders abnormal uterine bleeding (AUB), amenorrhea, dysmenorrhea (painful menstrual periods, and premenstrual syndrome (PMS) is on the rise across the globe, especially in the developing countries. In addition, increasing research and development activities, and technological advancements to identify the causes and risk factors for such disorders is fuelling the global myomectomy market growth. There is also an increasing demand for technologically advanced devices for the diagnosis of uterine fibroids. Increasing awareness about the reproductive health, and diseases among women across the globe also determine the growth of the market. The key players are now focusing on the geographical expansion in the developing regions such as Asia Pacific.
Uterine fibroids affects nearly 40% of women in the age group of 30 and 55, including 20 million women in North America and 24 million women in Europe with over 7 million patients worldwide presently undergo various symptom management treatments.
The global myomectomy market is expected to grow at a CAGR of 6.9% during the forecast period.
Major Players in Myomectomy Market:
Some of the key players in the global market are Halt Medical, Inc. (U.K), Boston Scientific Corporation (U.S.), CooperSurgical Inc. (U.S.), C. R. Bard, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), General Electric Company (U.S.), KARL STORZ SE & Co. KG (Germany), Richard Wolf Medical Instruments (U.S.), Siemens (U.S.), AbbVie Inc. (U.S.), Bayer (Germany), Eli Lilly and Company (U.S.), Johnson & Johnson Services Inc. (U.S.) and others
Browse Full Report @ [FURL=https://www.marketresearchfuture.com/reports/myomectomy-market-5149/]Click Here[/FURL] .